StreetAlpha.app
Home › Stocks › AVBP

ArriVent BioPharma, Inc. (AVBP)

Healthcare
$10.69
▼ −7.53%
LAST CLOSE · NOV 17

ArriVent BioPharma develops cancer medicines, led by firmonertinib for certain types of lung cancer. It last closed at $10.69 on Nov 17, down 7.53% on the day. The average 12-month price target from 7 analysts is $25.57 (+139.2% from the last close), with a high of $29.00 and a low of $20.00. Analyst consensus is Strong Buy, based on the latest ratings from 7 firms (7 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $316K, the largest $316K.

AI Auto Pilots
Is AVBP in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$169.1M
EPS (diluted)
−$3.60
Valuation
Market cap
$552.9M
51.7M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$113.6M
At Sep 30
Shareholder equity
$393.5M
Shares outstanding
51.7M
At Nov 5
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: −$69.3M−$69.3MFY2023FY2024: −$80.5M−$80.5MFY2024FY2025: −$166.3M−$166.3MFY2025

From AVBP's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 7 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
7firms
7 Buy0 Hold0 Sell
Each firm's latest rating on AVBP in the past 90 days
Average 12-month target
$25.57
▲ 139.2% upside

Based on 7 analysts who set a price target on AVBP in the past 90 days. The average target is $25.57, with a high of $29.00 and a low of $20.00, compared with the last close of $10.69.

Low $20.00Avg $25.57High $29.00
Blue marker: last close $10.69
Highest target$29.00
Average target$25.57
Lowest target$20.00
Latest rating changes
GuggenheimTarget lowered
Nov 16Buy$30 → $28
Truist SecuritiesTarget raised
Nov 10Buy$18 → $24
GuggenheimTarget raised
Oct 27Buy$18 → $30
B. Riley SecuritiesMaintained
Oct 20Buy$29
HC Wainwright & Co.Target lowered
Oct 8Buy$47 → $27
DateFirmActionRatingPrice target
Nov 16GuggenheimTarget loweredBuy$30 → $28
Nov 10Truist SecuritiesTarget raisedBuy$18 → $24
Oct 27GuggenheimTarget raisedBuy$18 → $30
Oct 20B. Riley SecuritiesMaintainedBuy$29
Oct 8HC Wainwright & Co.Target loweredBuy$47 → $27
Loading…

Technical Analysis

AVBP · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 36% below its 20 day and 92% below its 50 day average. It is 147% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 28), oversold. The nearest support is the 52 week low at $10.49, and the nearest resistance the Pivot at $11.02.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 13.7%/day
Key levels
$35.8352 week high+235.2%
$26.37200 day average+146.7%
$25.92100 day average+142.5%
$20.5850 day average+92.5%
$15.05Swing high (Nov 10)+40.8%
$14.5920 day average+36.5%
$11.54Pivot R1+8.0%
$11.02Pivot+3.1%
$10.69Last close
$10.4952 week low−1.9%
$10.17Pivot S1−4.9%
Indicators
RSI (14)27.96Oversold below 30Oversold
MACD-2.37Above its signal lineBullish
Stochastic8.8Near the bottom of its rangeOversold
ADX (14)33.4Trending down
Williams %R-96.7Oversold below −80, overbought above −20Oversold
CCI (20)-127.5Oversold below −100, overbought above 100Oversold
Rate of change−17.9%Change over 10 sessionsBearish
ATR (14)$1.46Typical daily range, 13.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for AVBP

What happened before

See how AVBP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in AVBP in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$316K
Largest print
$316K
Loading…

AVBP Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲85 buying vs 61 selling
  • ▲Held by funds +8.4 pts
  • ▼Funds holding -5
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding153158−3.2%
In funds' top 1011110.0%
Held by funds97.6%89.2%+8.4 pts
New / increased15 / 7034 / 70−18.3%
Reduced / sold out41 / 2030 / 15+35.6%
Put/call ratio1.270.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AVBP institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AVBP is in one of them and how their past AVBP trades turned out.

AVBP in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AVBP in an article yet. Here's the latest on the wider market.

About ArriVent BioPharma

ArriVent BioPharma is a clinical stage biopharmaceutical company based in Newtown Square, Pennsylvania. It develops cancer treatments for patients, with its lead candidate, firmonertinib, aimed at non-small cell lung cancer linked to certain EGFR gene mutations. The company is also developing antibody drug conjugates, including ARR 217, for solid tumors. Its candidates are still in clinical trials and have not been approved by the U.S. Food and Drug Administration.

Headquarters
Newtown Square, PA